Christopher Short, PhD is an expert in Pulmonology at Royal Brompton Hospital (United Kingdom). Christopher Short has authored 59 publications, the most recent in 2026, and is an investigator in 3 clinical trials, 1 of them ongoing. SLR score: 166 (community average: 125). How the SLR is computed.

LeadR Profile

Christopher Short, PhD Royal Brompton Hospital United Kingdom
166 ScienceLeadR Reputation 166
Network Map

Pulmonology

Subspecialties: Nephrology - Pediatrics - Gastroenterology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2015 - 2026

Source: PubMed

Royal Brompton Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Postural Influence on Ventilation Efficiency and Relationship With Oxygen-Enhanced MRI in Cystic Fibrosis.
PMID 42400509 — lung, fibrosis, cystic fibrosis, posture, pediatrics, ventilation
Pediatr Pulmonol20260
Maternal, Infant, Reproductive and Child Health in Cystic Fibrosis (MATRIARCH_CF): a prospective, observational study to evaluate pregnancy and parenthood in females with cystic fibrosis and health of the offspring in the CFTR-modulator era.
PMID 42379640 — pregnancy, parenting, lung, fibrosis, liver, breast feeding, aged, cystic fibrosis, child health, research, child, infant, neurodevelopment
BMJ Open Respir Res20261
Oxygen-enhanced MRI and multiple breath washout with Short extension reveal cystic fibrosis lung disease progression despite triple modulator therapy.
PMID 42235961 — lung, fibrosis, disease progression, cystic fibrosis, therapeutics, lung diseases
Thorax20260
Impact of two years of treatment with Elexacaftor/Tezacaftor/Ivacaftor on longitudinal changes in structural lung disease in people with Cystic Fibrosis - Results from the RECOVER trial.
PMID 41973991 — lung, blood, fibrosis, respiratory tract diseases, air, aged, cystic fibrosis, blood volume, therapeutics, lung diseases, mutation
Ann Am Thorac Soc20260
ENHANCE: a community partnership charting the evolution of early-life cystic fibrosis disease manifestations in a new era of management.
PMID 41878283 — lung, natural history, infant, newborn, fibrosis, liver, spirometry, cystic fibrosis, therapeutics, history, gastrointestinal microbiome, child, infant
ERJ Open Res20260

Clinical Studies 3

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 1
Phase 3 1
Phase 4 1

By status:

Active not recruiting 1
Completed 1
Recruiting 1

By type:

Interventional 2
Observational 1

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 1
multicentricup10 0

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study of Females With CF Throughout Pregnancy and Post partum and Follow up of Their Offspring
NCT06797206 — pregnancy, parenting, infant, newborn, fibrosis, cystic fibrosis, infant, female, women
N/ARecruiting2025

LeadR Networks

Main global connection map